Compare Davita Inc (DVA) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Payoneer Global Inc — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while Payoneer Global Inc trades at $7.08 (market cap $2.40B). The key difference: Davita Inc is far larger — about 4.9× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | PAYO | |
|---|---|---|
Market Cap | $11.72B | $2.40B |
Sector | Health | Technology |
52-Week High | $240.96 | $7.17 |
52-Week Low | $103.87 | $4.27 |
Enterprise Value | $24.44B | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Payoneer Global Inc. (PAYO) trades at $7.10, down 0.14% on the day, with a neutral technical signal and mixed earnings history. The company reported Q2 2026 EPS of $0.02, missing estimates, but revenue grew 10% year-over-year. Analysts maintain a 60% buy rating with an $8.20 consensus target, while the pending acquisition by Nuvei for $7.40 per share dominates news, prompting legal scrutiny over fairness.
Outlook is clouded by acquisition uncertainty; upside exists if the deal price is raised, but execution risks and margin pressure persist. Investors face near-term volatility from merger developments, with fundamental growth in B2B payments offering long-term potential if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
